ENT Disorder Treatment Market 2019 | See Incredible Growth by Top Players Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc

The Global ENT Disorder Treatment Market, by Organ Type (Ear, Nose, and Throat), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 9,521.1 million in 2016 and is projected to exhibit a CAGR of 3.2% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights.

The ENT Disorders treatment market is expected to gain significant traction with increasing incidence of ENT disorders and increasing environmental pollution globally. According to an article published by Harvard Medical School and Teaching Hospital, 2017, over 360 million people across the globe are suffering from hearing loss and over half of this population can be treated with proper medication and care.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1326

Manufacturers are focusing on development new and innovative treatments and therapies for ENT disorders for both adult and pediatric segments, in order to maintain their market share. For instance, Otonomy, Inc. — a U.S. based drug manufacturer — received FDA approval for OTIPRIO (ciproflaxin otic suspension) in December 2015, for treatment of pediatric patients suffering with bilateral otitis media with effusion. In May 2012, Meda Pharmaceuticals received FDA approval for dymista (azelastine hydrochloride and fluticasone propionate) for the treatment of seasonal allergic rhinitis that can be consumed by intranasal administration or sprayed suspension. Furthermore, in June 2017, Inspire Medical Systems received FDA approval for Inspire 3028 neurostimulator for the treatment of obstructive sleep apnea.

Key players are focusing on strategic merger and acquisition strategies for development and commercialization of novel ENT therapeutics and medical devices. For instance, December 2017, Entellus Medical, Inc. — a leader in ENT drugs segment — entered a definitive merger agreement with Stryker Corporation for development of effective ENT solutions through collaboration. Moreover, in in July 2017, Entellus Medical acquired Spirox, Inc. a privately held company that manufactures, develops and markets ENT medical devices.

Among treatment type segment, drug segment holds a dominant position in the global ENT disorder treatment market. This is owing to drug being the first line of treatment in most of the ENT disorders.
Among end users, hospital segment holds a dominant position in the global ENT disorder treatment market, as most of the surgical, non-surgical as well as consultation procedures are conducted at hospitals.

Some of the major players operating in the global ENT disorder treatment market include Sanofi, AstraZeneca plc, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1326

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.